UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

Journal of clinical oncology, 2015-03, Vol.33 (7), p.692-700

2015

Volltextzugriff (PDF)

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of clinical oncology, 2009-02, Vol.27 (5), p.663-671

2009

Volltextzugriff (PDF)

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

The New England journal of medicine, 2009-04, Vol.360 (14), p.1408-1417

2009

Volltextzugriff (PDF)

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

The lancet oncology, 2011-08, Vol.12 (8), p.795-805

2011

Volltextzugriff (PDF)

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Clinical cancer research, 2016-07, Vol.22 (13), p.3260-3267

2016

Volltextzugriff (PDF)

Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition

Acta neuropathologica communications, 2023-03, Vol.11 (1), p.41-41, Article 41

2023

Volltextzugriff (PDF)

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

CPT: pharmacometrics and systems pharmacology, 2021-05, Vol.10 (5), p.428-440

2021

Volltextzugriff (PDF)

Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling

Molecular biology of the cell, 2002-03, Vol.13 (3), p.978-988

2002

Volltextzugriff (PDF)

Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non-Small Cell Lung Cancer

Clinical cancer research, 2014-09, Vol.20 (17), p.4478-4487

2014

Volltextzugriff (PDF)

Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1181-1189

2010

Volltextzugriff (PDF)

Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer

Journal of clinical oncology, 2009-06, Vol.27 (17), p.2751-2757

2009

Volltextzugriff (PDF)

Death by a thousand cuts: an ever increasing list of caspase substrates

Cell death and differentiation, 1998-12, Vol.5 (12), p.997-1000

1998

Volltextzugriff (PDF)

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

Cancers, 2020-10, Vol.12 (10), p.3050

2020

Volltextzugriff (PDF)

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping

Cancer treatment reviews, 2020-07, Vol.87, p.102022, Article 102022

2020

Volltextzugriff (PDF)

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

iScience, 2020-12, Vol.23 (12), p.101832-101832, Article 101832

2020

Volltextzugriff (PDF)

Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis

Oncogene, 2000-09, Vol.19 (40), p.4563-4573

2000

Volltextzugriff (PDF)

P2X7/P2Z Purinoreceptor-mediated Activation of Transcription Factor NFAT in Microglial Cells

The Journal of biological chemistry, 1999-05, Vol.274 (19), p.13205-13210

1999

Volltextzugriff (PDF)

Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21057-e21057

2023

Volltextzugriff (PDF)

Treatment outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21056-e21056

2023

Volltextzugriff (PDF)

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

The New England journal of medicine, 2020-09, Vol.383 (10), p.931-943

2020

Volltextzugriff (PDF)

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

Molecular cancer therapeutics, 2023-07, Vol.22 (7), p.833-843

2023

Volltextzugriff (PDF)

IgG1 anti‐epidermal growth factor receptor antibodies induce CD8‐dependent antitumor activity

International journal of cancer, 2015-02, Vol.136 (4), p.821-830

2015

Volltextzugriff (PDF)

Abstract 3774: Unraveling mechanisms of resistance to tepotinib and future treatment options

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3774-3774

2020

Volltextzugriff (PDF)

Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases

Lung cancer (Amsterdam, Netherlands), 2022-01, Vol.163, p.77-86

2022

Volltextzugriff (PDF)

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification ( MET amp) detected by liquid biopsy (LBx)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9121-9121

2022

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(134)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(50)
Life Sciences & Biomedicine
(45)
Humans
(32)
Oncology
(19)
Animals
(15)
Male
(15)
Female
(13)
Mutation
(13)
Adult
(9)
Biological And Medical Sciences
(9)
Tumors
(9)
Apoptosis
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(8)
Cetuximab
(8)
Mice
(8)
Aged
(7)
Cell Biology
(7)
Lung Neoplasms - Drug Therapy
(7)
Medical Sciences
(7)
Middle Aged
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling

Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non-Small Cell Lung Cancer

Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study

Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer

Death by a thousand cuts: an ever increasing list of caspase substrates

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis

P2X7/P2Z Purinoreceptor-mediated Activation of Transcription Factor NFAT in Microglial Cells

Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification

Treatment outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations

IgG1 anti‐epidermal growth factor receptor antibodies induce CD8‐dependent antitumor activity

Abstract 3774: Unraveling mechanisms of resistance to tepotinib and future treatment options

Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases

Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification ( MET amp) detected by liquid biopsy (LBx)

Suchergebnisse filtern